Cardiology

Below, please find links to all of the clinical trials involving cardiology. The studies include a multitude of information, including (but not limited to) the study’s purpose, benefits for participating, and financial incentive information. If you have any questions, please contact the individual outlined at the end of each trial summary.

Please visit the Cardiology service webpage at the Veterinary Medical Teaching Hospital (VMTH) if you would like to learn more about the amazing things that our veterinarians can do for you and your animal.

Dogs

Lymphoma (B-cell): Understanding the Effect of a Lymphoma Treatment on Cardiac Arrhythmias

Title: The Effect of IV Infusion of Doxorubicin on the Incidence of Cardiac Arrhythmias and Cardiac Troponin I Levels in Dogs

Purpose of Study: Doxorubicin is currently the mainstay of treatment for dogs with B-cell lymphoma. This drug is known to be toxic to cardiac muscle cells; however, this toxicity is unavoidable, as the drug is so critically important in treatment of the disease. Currently, the only method for monitoring this toxic effect is echocardiography, which is expensive and only able to identify toxic changes once they become severe. The aim of this study is to determine whether monitoring of arrhythmia or blood markers of cardiac cell death can provide an early warning system for detecting the toxic effects of the drug.

Participation Requirements:

  • Ineligible:
    • Evidence of pre-existing cardiomyopathy
    • Previous history of arrhythmia
    • Currently receiving anti-arrhythmic therapy
    • Previous history of thoracic radiation therapy

Initial Evaluation for Participation: B-cell lymphoma must be diagnosed at UC Davis.

Procedures: Once your dog has been diagnosed with lymphoma and is undergoing treatment with chemotherapy including doxorubicin, the dog will need to have a heart ultrasound (echocardiography), heart rhythm monitoring with a Holter monitor, and blood sample collected before treatment with doxorubicin and at each doxorubicin treatment. Approximately 1-2 tbsp of blood will be taken at your dog's appointment after doxorubicin treatment for the Troponin test. This testing will occur around the same time as each dose of doxorubicin. Heart rhythm monitoring will be collected for 24 hours after some visits (i.e., your dog will go home wearing the monitor) and for only 1 hour in the hospital at other visits. Holter monitoring provides a continuous recording of the heart rhythm during your dog's normal activity. The monitor is worn for 24 hours. Five electrodes (small conducting patches) are placed on the chest. We need to shave the skin to connect each corresponding electrode.  Once attached to the cables, electrodes will be taped onto the chest and attached to a small battery-operated recording monitor. Your dog will be fitted with a vest and the monitor carried in the pocket.

Benefits: Your dog will receive free screening for a heart condition at the beginning of the study at no cost to you and you will be informed of any abnormal findings. These results may be used to adjust the chemotherapy plan and/or recommend future monitoring of your dog. The findings of this study, if validated, may used to help improve the safety and monitoring during treatment for future patients receiving doxorubicin.

Owner Responsibilities: The owner is responsible for paying for all costs associated with the diagnosis and treatment of B-cell lymphoma ($5000-6000). Assessment and monitoring costs of the echocardiograph, arrhythmia (via Holter) and any cardiac cellular damage as will be paid for by the study (~$1200). The owner will also be responsible for repair or replacement of the monitor or cables if damaged by water or sharp objects, respectively.

Contact: Teri Guerrero (530-752-0125 or tguerrero@ucdavis.edu)

Pulmonary Hypertension: Understanding the Genetics

Title: The Role of Genetics in Canine Pulmonary Hypertension and the Response to Standard Treatment with Sildenafil

Purpose: We are investigating the role of a common canine genetic variant on the condition of pulmonary hypertension. This genetic variant is being evaluated to see if it impacts the severity of disease or the response to the oral medication, sildenafil citrate, the most commonly used drug for the treatment of this condition. Information provided by this study will provide better guidelines for the treatment of dogs with pulmonary hypertension.

Participation Requirements: Dogs diagnosed with pulmonary hypertension

Initial Evaluation for Participation: 

  • Diagnosis of pulmonary hypertension confirmed by a complete echocardiographic study that was done by the UC Davis VMTH Cardiology service; and,
  • A recommendation from the veterinarian to give oral sildenafil for treatment of the condition.

Procedures: If you agree to be involved in this study:

  • Initial visit: We will collect a small blood sample and then perform a non-invasive assessment of blood flow, which will involve shaving a small area (the size of a postage stamp). You will be asked to give the sildenafil orally to your dog as prescribed by your veterinarian.
  • 25-35 days later: We need you to return to the hospital while your pet is receiving the medication to have the echocardiogram, blood sampling and shaved patch for vascular function assessment performed again.
  • You (the owner) will be asked to fill out a brief health questionnaire for your dog at each visit.

Benefits: There is no charge for you to allow your dog to participate in this clinical trial. The study will cover all costs associated with the diagnostic tests, examination fees and the 1-month supply of sildenafil medication. You will be responsible for covering costs associated with any adverse effects that your dog experiences secondary to the prescribed medication.

We cannot promise any benefits to your dog or other animals from your taking part in this clinical trial; however, possible benefits include better understanding of the disease process and mechanisms for predicting patients response to medical therapy.

Owner Responsibilities: You will be asked to complete two brief questionnaires (one at each visit), administer all prescribed medications for at least 30 days, and return while your pet is receiving this medication for a reevaluation appointment at the end of the 30-day period.

Contact: For more information, please contact Dr. Joshua Stern at jstern@ucdavis.edu or 530-752-2475